Drug Pricing and Value in Oncology

  • Patricia M. DanzonEmail author
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 213)


This paper first reviews the evidence on price levels, price growth, and value for cancer drugs. The available evidence suggests that prices for originator (brand-name) drugs are rising significantly more rapidly than general inflation, but the available data are inadequate for robust comparisons between cancer and other categories of specialty drugs. We then examine the factors contributing to high and rising prices for cancer drugs. This analysis focuses mainly on the USA, which accounts for 46% of global expenditures on cancer drugs. It is the country of first launch for most cancer and other specialty drugs and frequently has the highest prices for drugs.


Cancer drugs Pricing Reimbursement Affordability R&D 


  1. Bach PB (2009) Limits on Medicare’s ability to control rising spending on cancer drugs. N England J Med 360:626–633CrossRefGoogle Scholar
  2. Bennette CS, Richards C, Sullivan S, Ramsey SD (2016) Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff. 35(5):805–812. Scholar
  3. Bradley R (2017) The cost of care: new insights into healthcare spending growth. Beyond the Numbers. U.S. Bureau of Labor Statistics June 2017 6 no 7.
  4. Commonwealth Fund (2017) Getting to the root of high prescription drug prices. Issue Brief July 17. Commonwealthfund.orgGoogle Scholar
  5. Danzon PM (2012) Regulation of price and reimbursement for pharmaceuticals. In: Danzon P, Nicholson S (eds) The Oxford handbook of the economics of the biopharmaceutical industry. Oxford University Press, OxfordCrossRefGoogle Scholar
  6. Danzon PM (2014) Pricing and reimbursement for biopharmaceuticals and medical devices in the USA. In: Culyer AJ (ed) Encyclopedia of health economics, vol 3. Elsevier, San Diego, pp 127–135CrossRefGoogle Scholar
  7. Danzon PM, Furukawa M (2003) Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs Web Exclusive, Oct 2003.
  8. Danzon PM, Furukawa M (2006) Prices and availability of biopharmaceuticals: an international comparison. Health Aff 25(5):1353–1362CrossRefGoogle Scholar
  9. Danzon PM, Wang YR, Wang L (2005) The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ 14(3):269–292CrossRefGoogle Scholar
  10. Danzon PM, Mulcahy AW, Towse AK (2013a) Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement. Health Econ 24:238–252. Scholar
  11. Danzon PM, Towse A, Ferrandiz JM (2013b) Value-based differential pricing: efficient prices for drugs in a global context. Health Econ 24:294–301. Scholar
  12. DiMasi J, Grabowski H, Hansen R (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47:20–33.CrossRefGoogle Scholar
  13. Drummond MF, Sculpher M, Claxton K et al (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University PressGoogle Scholar
  14. Dusetzina SB (2016) Drug pricing trends for orally administered anti-cancer medications reimbursed by commercial health plans, 2000–2014. JAMA Oncol 2(7):960–961CrossRefGoogle Scholar
  15. Goldstein DA et al (2016) Global differences in cancer drug prices: a comparative analysis. J Clin Oncol 34(Supple):LBA6500CrossRefGoogle Scholar
  16. Gordon N et al (2016) Price trajectory of individual cancer drugs following launch. J Clin Oncol 34(Suppl):6502CrossRefGoogle Scholar
  17. Howard DH, Bach PB, Berndt ER et al (2015) Pricing in the market for anticancer drugs. J Econ Perspect 29:139–162CrossRefGoogle Scholar
  18. Kaiser Family Foundation (2017) The medicare prescription drug benefit.
  19. Kyle M (2007) Pharmaceutical price controls and entry strategies. Rev Econ Stat 89(1):88–99CrossRefGoogle Scholar
  20. Newman PJ, Sanders JD, Russell LB, Siegel JE, Ganiats TG (2017) Cost-effectiveness in health and medicine. Oxford University PressGoogle Scholar
  21. Prasad V et al (2016) The rising price of cancer drugs: a new old problem? JAMA Oncol 3:277–278CrossRefGoogle Scholar
  22. Prasad Vinay, de Jesus Kevin, Mailankody Sham (2017) The high price of anticancer drugs: origins, implications, barriers and solutions. Nat Rev Clin Oncol 14:381–390CrossRefGoogle Scholar
  23. Schnipper LE et al (2015) American society of clinical oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33(23):2563–2577CrossRefGoogle Scholar
  24. Sculpher M, Claxton K, Pearson SD (2017) Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health 20(2):234–239CrossRefGoogle Scholar
  25. Stargardt T, Vandoros S (2014) Pricing and reimbursement regulation in Europe. In: Culyer AJ (ed) Encyclopedia of health economics, vol 3. Elsevier, San DiegoGoogle Scholar
  26. Vogler S, Vitry A, Babar ZU (2016) Cancer drugs in 16 European countries, Australia and New Zealand: a cross-country price comparison study. Lancet Oncol 17:39–47CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.The Wharton SchoolUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations